AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2017
Jul 5, 2017
31801_dirs_2017-07-05_e10595fb-f5f4-4112-ace3-ba451ccc6690.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2017-07-01
Reporting Person: Martin Samuel Bates (SVP and CFO)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $2.80 | 2021-08-05 | Common Stock (1000) | Direct | |
| Employee Stock Option (right to buy) | $6.37 | 2022-09-20 | Common Stock (5250) | Direct | |
| Employee Stock Option (right to buy) | $16.36 | 2023-07-01 | Common Stock (7500) | Direct | |
| Employee Stock Option (right to buy) | $13.45 | 2024-06-04 | Common Stock (12000) | Direct | |
| Employee Stock Option (right to buy) | $25.41 | 2025-06-10 | Common Stock (21000) | Direct | |
| Employee Stock Option (right to buy) | $4.72 | 2026-06-08 | Common Stock (21000) | Direct | |
| Employee Stock Option (right to buy) | $2.32 | 2027-06-15 | Common Stock (65000) | Direct |
Footnotes
F1: The option became exercisable as to 25% of the shares on 8/5/2012 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F2: The option became exercisable as to 25% of the shares on 9/20/2013 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F3: The option became exercisable as to 25% of the shares on 7/1/2014 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F4: The option became exercisable as to 25% of the shares on 6/4/2015 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5: The option became exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F6: The option became exercisable as to 25% of the shares on 6/8/2017 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F7: The option becomes exercisable as to 25% of the shares on 6/15/2018 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.